Time to complete remission is an independent determinant of survival after intensive chemotherapy in AML
Abstract
Abstract The purpose of this study was to explore and determine the optimal landmark for defining complete remission after intensive induction therapy that best correlates with long-term survival outcome among patients with newly diagnosed acute myeloid leukemia.
Article Details
Authors (14)
Rithin Nedumannil
1Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia
Michael Ashby
1Monash University, Australian Centre for Blood Diseases, Melbourne, Australia
James Rowland
4Department of Haematology, Princess Alexandra Hospital, Brisbane, QLD, Australia
Jacques A. J. Malherbe
5Department of Haematology, Fiona Stanley Hospital, Murdoch, WA, Australia
Jared Fairbank
7Department of Haematology, Royal Adelaide Hospital, Central Adelaide Health Network, Adelaide, SA, Australia
Kelli Gray
1Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia
Sun Loo
6Alfred Hospital, Melbourne, VIC, Australia
Matthew Wright
5Department of Haematology, Fiona Stanley Hospital, Murdoch, WA, Australia
John Reynolds
Clinical Haematology, Alfred Health, Melbourne, VIC, Australia
Devendra Hiwase
24The Royal Adelaide Hospital, Department of Haematology, Adelaide, Australia
Paula Marlton
1Princess Alexandra Hospital, Department of Haematology, Brisbane, Australia
Shaun Fleming
Ashish Bajel
5Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, University of Melbourne, Department of Clinical Haematology, Melbourne, Australia
Andrew H. Wei